Ankit Mahadevia
2019
In 2019, Ankit Mahadevia earned a total compensation of $1.8M as Chief Executive Officer at Spero Therapeutics, a 148% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $250,000 |
---|---|
Option Awards | $752,778 |
Salary | $497,083 |
Stock Awards | $285,023 |
Other | $792 |
Total | $1,785,676 |
Mahadevia received $752.8K in option awards, accounting for 42% of the total pay in 2019.
Mahadevia also received $250K in non-equity incentive plan, $497.1K in salary, $285K in stock awards and $792 in other compensation.
Rankings
In 2019, Ankit Mahadevia's compensation ranked 6,484th out of 13,971 executives tracked by ExecPay. In other words, Mahadevia earned more than 53.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,484 | 54th |
Manufacturing | 2,458 | 57th |
Chemicals And Allied Products | 896 | 59th |
Drugs | 760 | 60th |
Pharmaceutical Preparations | 557 | 60th |
Mahadevia's colleagues
We found two more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2019.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019